CAT

872.31

+1.31%↑

297.85

+3.99%↑

GEV.US

1,035.86

+2.87%↑

RTX

174.22

-1.21%↓

220.63

+0.7%↑

CAT

872.31

+1.31%↑

297.85

+3.99%↑

GEV.US

1,035.86

+2.87%↑

RTX

174.22

-1.21%↓

220.63

+0.7%↑

CAT

872.31

+1.31%↑

297.85

+3.99%↑

GEV.US

1,035.86

+2.87%↑

RTX

174.22

-1.21%↓

220.63

+0.7%↑

CAT

872.31

+1.31%↑

297.85

+3.99%↑

GEV.US

1,035.86

+2.87%↑

RTX

174.22

-1.21%↓

220.63

+0.7%↑

CAT

872.31

+1.31%↑

297.85

+3.99%↑

GEV.US

1,035.86

+2.87%↑

RTX

174.22

-1.21%↓

220.63

+0.7%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Deschisă

1.36 4.62

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.28

Maxim

1.3599999999999999

Indicatori cheie
By Trading Economics
Venit	-1.5M -19M
Vânzări	1.7M 1.5M
EPS	-0.06
Marjă de profit	-1,250.946
Angajați	116
EBITDA	-987K -17M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+763.43% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-173M 454M
Deschiderea anterioară	-3.26
Închiderea anterioară	1.36

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

0.6818 / 0.74 Suport & Rezistență

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 mai 2026, 20:36 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Câștiguri

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Câștiguri

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mai 2026, 22:02 UTC

Câștiguri

ZTO Express (Cayman): Di Xu to Resign From Board

19 mai 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mai 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mai 2026, 22:00 UTC

Câștiguri

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mai 2026, 21:37 UTC

Câștiguri

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mai 2026, 21:31 UTC

Achiziții, Fuziuni, Preluări

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mai 2026, 21:01 UTC

Câștiguri

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mai 2026, 20:58 UTC

Câștiguri

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mai 2026, 20:46 UTC

Acțiuni populare

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mai 2026, 20:34 UTC

Câștiguri

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries 4Q EPS 5c >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries 4Q Sales $1.4B >JHX

19 mai 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mai 2026, 20:03 UTC

Achiziții, Fuziuni, Preluări

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mai 2026, 20:03 UTC

Achiziții, Fuziuni, Preluări

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mai 2026, 20:02 UTC

Achiziții, Fuziuni, Preluări

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mai 2026, 20:02 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

763.43% sus

Prognoză pe 12 luni

Medie 11.57 USD 763.43%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.